> Israel's XTL Biopharmaceuticals has raised $28 million from a private placement. Report
> Canada's Wex Pharmaceuticals is handing out pink slips to about half of its 100 workers as it moves to shave about a million dollars in annual expenses. Earlier this month Wex announced unfavorable interim results for a study of its cancer-pain therapy Tectin. Report
> A hedge fund that owns 9 percent of Chiron refused to meet with the drug developer as Chiron works to woo shareholders for their support of Novartis' offer to buy the 56 percent of Chiron shares it doesn't already own. ValueAct says the $45 bid, a discount on Chiron's $45.77 Friday close, was woefully inadequate. Report
> Eli Lilly and Biosite have agreed to collaborate on a trial of Lilly's Xigris. Report
> Antisoma has completed patient recruitment into a Phase II trial of AS1404 in ovarian cancer. Release
> Tm Bioscience has acquired sepsis biomarkers from Sirius Genomics. Release
> Roche shares surged on Genentech's announcement late last week that it was raising its earnings forecast. Report
And Finally... An Internet game that tracks the journey of U.S. currency could prove invaluable in tracking the spread of a U.S. pandemic. Seventy-nine million bills have been registered so far. Article